Sugi Predict

Sugi Predict / Compounds / SCHEMBL17420712

SCHEMBL17420712

SCHEMBL17420712

CCOC(=O)C(=O)c1ccc(F)cc1OCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.51
▸ MAPT P10636 2/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ TSHR P16473 3/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ TDP1 Q9NUW8 3/20 0.42
▸ GAA P10253 1/20 0.42
▸ MRGPRX1 Q96LB2 3/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30628212 1.00 KDM4E (0.51) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL1673470 0.88 MAPT (0.48) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL30628290 0.88 MAPT (0.48) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL17420478 0.88 MAPT (0.48) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL17420753 0.88 MRGPRX1 (0.45) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL1546433 0.84 TSHR (0.54) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL30628248 0.84 MAPT (0.44) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL17420503 0.84 MAPT (0.44) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL20505287 0.83 KDM4E (0.53) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL1521930 0.83 MAPT (0.51) KDM4EMAPTCYP1A2CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111170991-B Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2023-10-31 — — CN disclosed
EP-3594211-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2023-10-25 — — EP disclosed
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2022-12-08 — — US disclosed
US-11241423-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2022-02-08 — — US disclosed
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2020-05-28 — — US disclosed
CN-111170991-A Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2020-05-19 — — CN disclosed
CN-106660991-B Antiproliferative compounds and methods of use thereof 细胞基因公司 2020-03-13 — — CN disclosed
EP-3166937-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2019-09-04 — — EP disclosed
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-08-09 — — US disclosed
US-9968596-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2018-05-15 — — US disclosed
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-01-25 — — US disclosed
US-9808451-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2017-11-07 — — US disclosed
EP-3166937-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF Celgene Corporation (US) 2017-05-17 — — EP disclosed
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2017-01-12 — — US disclosed
US-9499514-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2016-11-22 — — US disclosed
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION 2016-01-14 — — US disclosed
WO-2016007848-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION (US) 2016-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KDM4E 1196/4885MAPT 4744/4885CYP1A2 2288/4885
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KDM4E 1196/4885MAPT 4744/4885CYP1A2 2288/4885
US-11241423-B2 Antiproliferative compounds and methods of use thereof MCL1, MKI67, BAX KDM4E 1196/4885MAPT 4744/4885CYP1A2 2288/4885
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KDM4E 1196/4885MAPT 4744/4885CYP1A2 2288/4885
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KDM4E 1196/4885MAPT 4744/4885CYP1A2 2288/4885
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KDM4E 1196/4885MAPT 4744/4885CYP1A2 2288/4885
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KDM4E 1196/4885MAPT 4744/4885CYP1A2 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.